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Abstract
Background: Financial ties between health professionals and industry may unduly influence professional judgments and
some researchers have suggested that widening disease definitions may be one driver of over-diagnosis, bringing
potentially unnecessary labeling and harm. We aimed to identify guidelines in which disease definitions were changed, to
assess whether any proposed changes would increase the numbers of individuals considered to have the disease, whether
potential harms of expanding disease definitions were investigated, and the extent of members’ industry ties.
Methods and Findings: We undertook a cross-sectional study of the most recent publication between 2000 and 2013 from
national and international guideline panels making decisions about definitions or diagnostic criteria for common conditions
in the United States. We assessed whether proposed changes widened or narrowed disease definitions, rationales offered,
mention of potential harms of those changes, and the nature and extent of disclosed ties between members and
pharmaceutical or device companies. Of 16 publications on 14 common conditions, ten proposed changes widening and
one narrowing definitions. For five, impact was unclear. Widening fell into three categories: creating ‘‘pre-disease’’; lowering
diagnostic thresholds; and proposing earlier or different diagnostic methods. Rationales included standardising diagnostic
criteria and new evidence about risks for people previously considered to not have the disease. No publication included
rigorous assessment of potential harms of proposed changes. Among 14 panels with disclosures, the average proportion
of members with industry ties was 75%. Twelve were chaired by people with ties. For members with ties, the median
number of companies to which they had ties was seven. Companies with ties to the highest proportions of members were
active in the relevant therapeutic area. Limitations arise from reliance on only disclosed ties, and exclusion of conditions too
broad to enable analysis of single panel publications.
Conclusions: For the common conditions studied, a majority of panels proposed changes to disease definitions that
increased the number of individuals considered to have the disease, none reported rigorous assessment of potential harms
of that widening, and most had a majority of members disclosing financial ties to pharmaceutical companies.
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Introduction
Changes in technologies, treatments, medical knowledge, and
cultural norms provide cause to review and change disease
definitions and diagnostic thresholds, a task that is commonly
undertaken by expert panels, consensus meetings, or influential
workgroups who publish findings as statements, special reports, or
as part of clinical practice guidelines. While such changes can be
beneficial, there is an increasing recognition that widening of
disease definitions may be one factor contributing to the problem
of over-diagnosis, occurring across a range of conditions including
pulmonary embolism, breast and prostate cancers [1,2]. The
concern expressed by some researchers is that for some people
with milder symptoms, at lower risks, or in earlier stages of possible
disease, the harms of a diagnostic label and treatment may
outweigh benefits [3,4].
At the same time there is accumulating evidence about
pervasive financial ties between pharmaceutical companies and
health professionals [5], including those writing guidelines [6] and
disease definitions [7]. While noting the value of professional–
industry collaborations, a 2009 Institute of Medicine (IOM) report
found ‘‘widespread relationships with industry have created
significant risks that individual and institutional financial interests
may unduly influence professionals’ judgments,’’ and that these
‘‘conflicts of interest’’ threaten the integrity of research, the
objectivity of education, the quality of patient care, and public
trust in medicine [5].
The 2009 report recommended professional societies and other
organisations drafting clinical practice guidelines should ‘‘generally
exclude as panel members individuals with conflicts of interest.’’ A
subsequent 2011 IOM report on how to produce trustworthy
guidelines included recommendations that ‘‘whenever possible,’’
guideline developers ‘‘should not have’’ conflicts of interest, that
only a minority should have conflicts, and that chairs should be
free of conflicts [8].
As both reports make clear, in addition to financial ties there are
non-financial or intellectual conflicts such as academic advance-
ment, and there should be no assumption that having a conflict is
unethical, or ‘‘that any particular professional will necessarily let
financial gain influence his or her judgment’’ [5].
A 2011 systematic review found many clinical guideline panels
have failed to disclose financial ties, and those that did disclose had
a ‘‘high percentage’’ of individuals with financial conflicts of
interest [6]. Studies analysing ties of working groups for the
Diagnostic and Statistical Manual of Mental Disorders (DSM),
which set definitions and diagnostic criteria, have also found a
majority of members with ties [7]. Kung and colleagues recently
found two-thirds of individuals chairing guideline committees had
conflicts of interest [9].
Few studies [7] have examined the financial ties of members of
panels reviewing and changing definitions of common conditions,
whether as part of practice guideline development or other
processes. Our aim was to identify guideline panels in the US
setting that have most recently made decisions about definitions or
diagnostic thresholds for common conditions, and to report on any
proposed changes and their industry ties.
Methods
List of Conditions
On the basis of the method previously used by Choudhry and
colleagues [10], we derived a list of common conditions in the
United States, drawing from a list of the ten most costly adult
diseases [11], the top 20 therapeutic classes of drugs, and the top
25 individual drugs by expenditure [12]. Consistent with that
method, drugs used to treat many non-specific conditions were
excluded (e.g., pain killers). For situations in which a drug was
approved for a number of conditions, we identified the most
common condition for inclusion (e.g., etanercept ultimately
mapped to rheumatoid arthritis, not psoriatic arthritis). If a
condition in the top ten costly disease list was too broad or diffuse,
or covered many specific conditions, it was excluded (e.g., back
problems). A flowchart of the method appears in Figure 1.
List of Panels and Publications
We aimed to identify the most recent publication from panels
making decisions about disease definition and diagnosis. A panel
publication was eligible for inclusion if it was generated or
supported by a widely recognised US-based organisation,
published between 2000 and April 2013, and included delibera-
tions and decisions on disease definitions and/or diagnostic
criteria, classification, or assessment. If the panel made decisions,
but proposed no changes, our search would continue for the most
recent publication proposing changes, to include as well. If the
focus of the panel publication was limited to specific sub-groups of
patients, (e.g., adolescents), specific sub-categories of the condition
(e.g., work-related asthma), it came from a single entity (e.g., a
health maintenance organisation), or it included treatment
recommendations but no review and deliberation on disease
definition or diagnostic criteria, it was excluded.
During a pilot phase, using the searches for the most recent
hypertension and asthma panel publications, an explicit search
strategy using standardized keywords was iteratively developed in
order to maximise sensitivity. We searched Medline (Ovid) using
terms for each disease/condition and combined these terms with a
standardized search strategy consisting of a string of MeSH and
keyword terms to identify panels and publications (example in
Table S1). Searches were run over 26–31 July 2012, updated 17–
18 April 2013, and limited to English language from 2000.
To further improve sensitivity and try to ensure recent
publications were not missed, two authors (RNM, GPEC)
independently analysed the results of the standardised Medline
searches for all conditions, and supplemented this with indepen-
dent individual searches of the websites of the relevant National
Institutes of Health and the National Guideline Clearing House.
For two conditions, minor discrepancies in independent sugges-
tions were resolved by discussion and, in one case (diabetes II), by
consultation with a third author (PPG). Because of their global
prominence and influence, if a panel was constituted under the
umbrella of the National Institutes of Health (NIH), or the
American Psychiatric Association’s DSM, and met our inclusion
criteria, these panels were identified for inclusion in our study. If
there was a more recent panel publication that also met the study’s
inclusion criteria, in addition to the NIH or DSM panel, we
included the more recent publication as well. This occurred twice
(asthma and high cholesterol), resulting in two publications being
identified for each condition.
Information on the Panels’ Decisions
For each publication we extracted information on key proposed
changes to definitions/diagnostic criteria, the rationale offered,
and any mention of potential harms associated with the proposed
changes (e.g., over-diagnosis, overtreatment, medicalizing normal-
ity, labelling asymptomatic people). All six authors then made an
assessment of whether the panel’s proposed key changes would
tend to widen (e.g., earlier diagnosis, lower thresholds, adding
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symptoms, increasing numbers diagnosed) or narrow the disease
definition, or whether it was unclear.
Information on Industry Ties
Using published disclosure sections from the panel publications,
duplicate independent extraction of data was conducted (RNM
and research assistant Peter Coxeter), with a third party resolving
any disagreement (PGG). Ties were categorized as speaker/
honorarium, consultant/adviser, grant/research, stock, employee,
travel, or royalties. Panel members were those listed as authors or
identified as the group with primary responsibility for generating
the publications. In line with the IOM approach [5], an industry
tie was defined as a tie to a pharmaceutical, diagnostic, device, or
biotechnology company, but not a communications or medical
education company. If there was any lack of clarity as to the nature
of the company, or uncertainty if it met study criteria, a tie was not
recorded. Once all industry ties were recorded for each panel,
websites of companies with financial ties to the three highest
proportions of panel members were searched to determine
whether those companies were active in the specific therapeutic
area. Where they appeared in disclosure sections, the disclosure of
any ties to public agencies, non-government organizations, and
publishers was also recorded.
Results
After analyzing source documents [11,12], the following drug
classes, individual drugs, and conditions were excluded when
identifying study conditions, as they were too non-specific or too
broad, and did not map to specific conditions enabling analysis:
oncologics; autoimmune diseases; narcotic analgesics; anti-epilep-
tics; vaccines; hormonal contraceptives; immunostimulating
agents; bevacizumab; oxycodone; pegfilgrastim; cancer; trauma-
related disorders; and back problems.
From an initial list of 16 included common conditions, for
two—osteoarthritis, HIV—we could identify no panel that made
decisions about definitions or diagnostic thresholds since 2000 in
the US context specifically. For the remaining 14 conditions, we
identified the most recent panels that deliberated and made
decisions about disease definitions, all of which proposed changes.
For asthma and high cholesterol we identified two panels each,
one constituted under the government funded NIH [13,14] and
one by professional societies [15,16], reflecting the two main types
of panels identified in this study. A single panel, the DSM-V Mood
Disorders working group, proposed changes to two different
conditions, bipolar and depression, in two separate web-based
publications [17]. A full list of the final 14 conditions, 15 panels
Figure 1. Flowchart identifying study conditions and panels reviewing definitions. Note: bipolar/depression was one panel.
doi:10.1371/journal.pmed.1001500.g001
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and 16 publications, key changes and rationale, analysis of panel
decisions, and disclosed ties appears in Table 1.
Among 16 publications, all authors in our study agreed that
proposals in ten publications would tend to widen definitions
(Table 2) and for one, narrow the definition. For the remaining
five publications the impact was unclear. Rationales for the
benefits of widening definitions or expanding diagnostic categories
included: evidence about the risk of future adverse events for
people previously considered normal (pre-hypertension); simplifi-
cation (gastroesophageal reflux disease [GERD]); standardisation
for research (rheumatoid arthritis); and the emergence of new
evidence about biomarkers, tests, or treatments (Alzheimer
disease). Among 15 panels, six included mention of possible harms
of proposed changes (Table 3), albeit briefly, with three of those
including citations in that mention [17–19], two citing primary
studies [18,19], and one of those citing a review of primary studies
as well [18]. One publication referred to the potential negative
consequences for those who would be labelled by the expanded
definition [20], and only one referred to overdiagnosis [21].
The average number of panel members was 21 (range, five to
52). Among 15 panels, 12 included members disclosing financial
ties to multiple companies, one panel disclosed ties to a single
company only (GERD) [21], one stated that members had no
relevant conflicts of interest (diabetes II) [22], and one had no
disclosure section (high cholesterol 2002) [14], also the oldest
panel. For a total of 2,081 individual ties across all categories
recorded in the study, there were 55 discrepancies, 2.6%, arising
from the independent extraction, mainly involving one or other
extractor accidentally missing or adding a specific tie, or making
errors by entering a specific tie into an adjacent column or row in
a spreadsheet. All were resolved by discussion.
Among 14 panels with disclosure sections, the average
proportion of members with industry ties was 75% (range 0%–
100%) (Table 4). For members with ties, the median number of
pharmaceutical or device companies to which they had declared
ties to was seven (Table 4). For the nine panel publications
disclosing multiple separate categories of tie, on average, members
with industry ties were a consultant/adviser for four companies,
received speaker fees/honoraria from two companies, and they or
Table 2. Different ways to expand disease definitions.
Method of Widening Disease Details
Creating new categories of pre-disease Hypertension Describes pre-hypertension
Alzheimer disease Describes pre-dementia and defines pre-clinical Alzheimer
disease
Lowering diagnostic thresholds High cholesterol 2002 Lowers cholesterol and triglyceride thresholds
ADHD Changes age of onset; adds new symptoms
Depression Removes bereavement exclusion
GERD Drops severity threshold for definition
Earlier diagnosis, different diagnostic method Rheumatoid arthritis Earlier diagnosis
Multiple sclerosis Single scan diagnosis, earlier identification
Myocardial Infarction More sensitive tests identifying more people
High cholesterol 2012 Additional new test
doi:10.1371/journal.pmed.1001500.t002
Table 3. Mention of possible harms of proposed changes to definitions.
Condition Panel Comments
ADHD [19] ‘‘main potential negative consequence of raising the age of onset is an increase in
prevalence’’
Alzheimer disease [30] ‘‘ethical and practical implications’’ of a ‘‘diagnosis’’ of AD at preclinical stage ‘‘need to
be studied’’
COPD [18] tests ‘‘may lead to more frequent diagnosis of COPD in older adults… as the normal
process of aging affects lung volumes and flows, and may lead to under-diagnosis in
adults younger than 45’’
Diabetes II [22] need to balance ‘‘stigma and costs of mistakenly identifying individuals as diabetic
against the minimal clinical consequences of delaying the diagnosis in someone with
an A1C level 6.5%’’
Mood Disorders panel (Bipolar and Depression) [17] to prevent ‘‘medicalization of normal fluctuations of mood’’ diagnoses should only be
applied when the ‘‘clinician determines that the symptoms are associated with
clinically significant distress or impairment that require clinical care’’
Myocardial infarction [20] ‘‘the current modification of the definition of MI may be associated with consequences
for the patients and their families in respect of psychological status, life insurance,
professional career…’’
Note: for all other panel publications we could identify no mentions.
doi:10.1371/journal.pmed.1001500.t003
Expanding Disease Definitions and Panel Ties
PLOS Medicine | www.plosmedicine.org 6 August 2013 | Volume 10 | Issue 8 | e1001500
T
a
b
le
4
.
N
at
u
re
an
d
e
xt
e
n
t
o
f
d
is
cl
o
se
d
ti
e
s,
b
y
p
an
e
l.
P
a
n
e
l
T
o
ta
l
N
u
m
b
e
r
o
f
In
d
u
st
ry
T
ie
s
b
y
C
a
te
g
o
ry
a
P
e
rc
e
n
t
M
e
m
b
e
rs
w
it
h
In
d
u
st
ry
T
ie
s
M
e
d
ia
n
n
(I
Q
R
)
C
o
m
p
a
n
ie
s
T
ie
d
to
P
e
rc
e
n
t
M
e
m
b
e
rs
w
it
h
N
o
n
-I
n
d
u
st
ry
T
ie
sc
S
p
e
a
k
e
r/
H
o
n
o
ra
ri
a
C
o
n
su
lt
a
n
t/
A
d
v
is
e
r
G
ra
n
t/
R
e
se
a
rc
h
O
th
e
rb
A
D
H
D
2
0
1
2
[1
9
]
1
0
6
9
2
5
/9
(5
6
%
)
2
(2
–
5
)
7
/9
(7
8
%
)
A
lz
h
e
im
e
r
d
is
e
as
e
2
0
1
1
[2
8
–
3
0
]
1
1
1
7
2
3
1
0
2
6
/4
6
(5
7
%
)
5
(2
–
7
)
6
/4
6
(1
3
%
)
A
n
e
m
ia
/C
K
D
2
0
1
2
[3
3
]
1
4
3
4
1
8
5
1
5
/1
7
(8
8
%
)
3
(2
–
4
)
n
/a
A
st
h
m
a
2
0
0
9
[1
5
]
6
7
1
2
1
9
9
6
2
3
/2
4
(9
6
%
)
6
(5
–
1
0
)
3
/2
4
(1
3
%
)
A
st
h
m
a
2
0
0
7
[1
3
]
5
3
1
0
3
6
6
0
1
6
/1
8
(8
9
%
)
7
(5
–
1
1
)
7
/1
8
(3
9
%
)
B
ip
o
la
r;
d
e
p
re
ss
io
n
2
0
1
2
[1
7
]
1
7
2
4
1
4
6
8
/1
2
(6
7
%
)
5
(3
–
6
)
1
0
/1
2
(8
3
%
)
C
h
o
le
st
e
ro
l
2
0
1
2
[1
6
]
2
5
1
5
1
0
0
7
/8
(8
8
%
)
4
(3
–
7
)
n
/a
C
O
P
D
2
0
1
1
d
[1
8
]
n
/a
n
/a
n
/a
n
/a
1
2
/1
2
(1
0
0
%
)
9
(8
–
1
2
)
1
/1
2
(8
%
)
H
yp
e
rt
e
n
si
o
n
2
0
0
3
[2
3
]
4
4
6
0
6
2
2
9
/1
1
(8
2
%
)
1
2
(1
1
–
1
3
)
3
/1
1
(2
7
%
)
M
S
2
0
1
0
[4
2
]
4
4
1
0
4
4
6
9
1
7
/1
8
(9
4
%
)
7
(5
–
1
0
)
1
5
/1
8
(8
3
%
)
M
I
2
0
1
2
d
[2
0
]
n
/a
n
/a
n
/a
n
/a
4
3
/5
2
(8
3
%
)
7
(3
–
1
2
)
1
1
/5
2
(2
1
%
)
R
A
2
0
1
0
d
[4
3
]
n
/a
n
/a
n
/a
n
/a
1
7
/3
5
(4
9
%
)
7
(5
–
9
)
1
/3
5
(3
%
)
a
In
d
iv
id
u
al
m
e
m
b
e
rs
ca
n
d
is
cl
o
se
ti
e
s
to
m
o
re
th
an
o
n
e
co
m
p
an
y.
b
O
th
e
r=
st
o
ck
,
e
m
p
lo
ye
e
,
tr
av
e
l,
ro
ya
lt
ie
s.
c
N
o
n
-i
n
d
u
st
ry
ti
e
s
in
cl
u
d
e
ti
e
s
to
p
u
b
lic
ag
e
n
ci
e
s,
n
o
n
-g
o
ve
rn
m
e
n
t
o
rg
an
iz
at
io
n
s,
an
d
p
u
b
lis
h
e
rs
;
so
m
e
d
is
cl
o
su
re
se
ct
io
n
s
d
id
n
o
t
in
cl
u
d
e
n
o
n
-i
n
d
u
st
ry
ti
e
s.
d
D
is
cl
o
su
re
se
ct
io
n
s
lu
m
p
e
d
so
m
e
ca
te
g
o
ri
e
s
to
g
e
th
e
r.
C
K
D
,
ch
ro
n
ic
ki
d
n
e
y
d
is
e
as
e
;
IQ
R
,
in
te
rq
u
ar
ti
le
ra
n
g
e
;
M
I,
m
yo
ca
rd
ia
l
in
fa
rc
ti
o
n
;
M
S,
m
u
lt
ip
le
sc
le
ro
si
s;
n
/a
,
n
o
t
av
ai
la
b
le
;
R
A
,
rh
e
u
m
at
o
id
ar
th
ri
ti
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
m
e
d
.1
0
0
1
5
0
0
.t
0
0
4
Expanding Disease Definitions and Panel Ties
PLOS Medicine | www.plosmedicine.org 7 August 2013 | Volume 10 | Issue 8 | e1001500
their institutions received research support from three. Twelve
panels were chaired or publications led by authors with industry
ties, most commonly to multiple companies. Among panels
disclosing any ties to government agencies, non-government
organisations, or publishers, on average around one-third of panel
members disclosed these ties.
For the 12 panels for which ties were disclosed to more than one
company, almost all companies with ties to the three highest
proportions of panel members were also active in the market for
that panel’s condition, with at least one drug on the market or in
the research pipeline (Table 5). For example, with the chronic
obstructive pulmonary disease [COPD] publication, Astra Zeneca,
Boehringer-Ingelheim, and GSK—all companies with drugs for
Table 5. Companies with highest proportions of ties, and drugs in therapeutic area.
Panela Top Companies
n and Percent of Panel to
Which Company Had Ties Drug in Therapeutic Area
ADHD [19] Janssen Cilag 3/9 (33%) Methylphenidate HCI
Eli Lilly 2/9 (22%) Atomoxetine HCI
McNeil 4/9 (44%) Methylphenidate HCI
Shire 2/9 (22%) Amphetamine (Adderall)
Alzheimer disease [28–30] Pfizer 13/46 (28%) Donepezil HCI
Eli Lilly 14/46 (30%) Solanezumab
Elan 11/46 (24%) Bapineuzumab
Anemia/CKD [33] Amgen 13/17 (76%) Darbepoetin alfa
Roche 5/17 (29%) Methoxy polyethylene glycol-epoetin beta
Affymax 5/17 (29%) Peginesatide
Vifor 4/17 (24%) Iron supplementation
Asthma 2009 [15] GSK 20/24 (83%) Fluticasone propionate
AZ 19/24 (79%) Zafirlukast
Novartis 14/24 (58%) Omalizumab
Asthma 2007 [13] AZ 11/18 (61%) Zafirlukast
GSK 12/18 (67%) Fluticasone propionate
Merck 13/18 (72%) Montelukast sodium
Bipolar/depression [17] AZ 3/12 (25%) Quetiapine fumerate
Lilly 5/12 (42%) Duloxetine; olanzapine
Pfizer 5/12 (42%) Sertraline HCI; ziprasidone HCI
Cholesterol 2012 [16] Merck 4/8 (50%) Simvastatin
Abbott 3/8 (38%) Niacin
AZ 3/8 (38%) Rosuvastatin
Novo-Nordisk 3/8 (38%) n/a
COPD [18] AZ 11/12 (92%) Budesonide & formoterol fumarate dihydrate
BI 11/12 (92%) Tiotropium bromide
GSK 11/12 (92%) Fluticasone propianate
Hypertension [23] BMS 8/11 (73%) Irbesartan
Merck 8/11 (73%) Losartan
Novartis 8/11 (73%) Amlodipine besylate/benazepril hydrochloride
Myocardial infarction [20] AZ 23/52 (44%) Rosuvastatin
Merck 16/52 (31%) Simvastatin
Bayer 15/52 (29%) Rivaroxaban
BI 15/52 (29%) Alteplase
Multiple sclerosis [42] Biogen 13/18 (72%) Interferon beta-1a
Merck Serono 12/18 (67%) Interferon beta
Sanofi 11/18 (61%) Teriflunomide
Rheumatoid arthritis [43] UCB 15/35 (43%) Certolizumab pegol
Abbott 14/35 (40%) Adalimumab
BMS 13/35 (37%) Abatacept
aAnalysis not possible for Cholesterol 2002, diabetes, GERD panels.
CKD, chronic kidney disease; n/a, not available.
doi:10.1371/journal.pmed.1001500.t005
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the condition—each had financial ties to 11 of 12 members,
including the chair [18]. With the DSM-V Mood Disorders work
group, Pfizer and Lilly—with drugs for depression and bipolar—
had ties to five of the 12 members [17]. Similarly, companies
marketing hypertension drugs—Bristol-Myers Squibb, Merck,
Novartis—each had financial ties to eight of the 11 members of
the panel which created the new diagnostic category ‘‘pre-
hypertension’’ [23].
To evaluate any potential impact of the IOM recommendations
regarding industry ties, we compared the panel publications
released in 2012—after both IOM reports [5,8]—to those released
earlier. We found similar proportions of members disclosing
industry ties (76% was the average across 2012 panels; 74% was
the average across pre-2012 panels); a small reduction in the
median number of companies to which those members disclosed
ties in the 2012 panels (four in 2012 panels; seven pre-2012
panels); and similar proportions of panel publications widening
definitions (four of six of 2012 publications; six of ten of pre-2012
publications).
Discussion
In this cross-sectional analysis of panels making recent decisions
on definitions of common conditions in the US context, we found
most panels proposed widening definitions and most had a
majority of members with multiple ties to pharmaceutical
companies. Proposals to widen fell into three inter-related
categories: creating new categories of ‘‘pre-disease’’; lowering
diagnostic thresholds; and proposing earlier diagnosis or different
diagnostic methods (Table 2). In some cases a clear rationale was
offered for these changes—as when the hypertension panel cited
evidence from original studies and meta-analysis linking normal
blood pressure with elevated risks as the reason to create ‘‘pre-
hypertension’’ [23]. In other publications, including the 2007
panel proposing changes to the diagnosis of asthma [13], the
rational was less clear, more complex and diffuse.
Notwithstanding the problem of under-diagnosis, a growing
body of evidence suggests over-diagnosis may be occurring across
a range of common conditions, including hypertension [24],
asthma [25], attention deficit hyperactivity disorder (ADHD) [26],
and COPD [27]. Yet less than half of the study publications
mentioned potential harms of proposed changes to definitions, and
none included a rigorous evidence-informed discussion of those
risks or how they might be mitigated.
In a three-part publication in 2011 [28–30] proposing new
categories of ‘‘pre-clinical’’ Alzheimer disease (for research only
at this stage) and ‘‘predementia’’—which would clearly expand
the population labelled—there was one short reference to the
need to study the ‘‘ethical and practical implications’’ of
diagnosing people at a ‘‘preclinical’’ stage [30]. The panel
proposing changes to assessment and classification of COPD
briefly mentioned that diagnostic methods ‘‘may lead to more
frequent diagnosis of COPD in older adults with mild COPD as
the normal process of aging affects lung volumes and flows’’ [18],
but did not explicitly refer to the risk of ‘‘over-diagnosis’’ as it had
done in a previous version of its report [31]. Proposing changes to
ADHD diagnostic criteria—in part to make the condition more
amenable to being a ‘‘lifespan’’ disorder involving adults as well
as children—the DSM-V panel mentioned potential increases in
prevalence but suggested they would be ‘‘negligible’’ (Table 3)
[32].
Among panels disclosing ties, almost all chairs had financial ties
to industry, and an average of three-quarters of members had ties
to a median of seven companies, commonly working as
consultants, advisers and/or speakers, as well as receiving research
support. Companies with financial relationships with the greatest
proportion of panel members were marketing or developing drugs
for the same conditions about which those members were making
critical judgements. GSK for example, marketing top-selling
products for asthma, had financial ties to 20 of the 24 members
of the 2009 asthma panel, and all 20 were consultant/advisers
and/or declared speaker/honoraria ties to GSK [15].
This study has several important limitations. First, the lack of a
comparison group means it is impossible to draw any inference of
association between frequency of industry ties and proposals to
change disease definitions. The exclusion of common conditions
too broad to enable a focussed analysis of single panel publications
(e.g., back problems) means it may have missed potentially
important examples of changing disease definitions and limits
generalizability of findings. The focus on the United States—
chosen explicitly because of its globally influential panels such as
DSM-V workgroups—also limits generalizability. A fourth limita-
tion is reliance solely on disclosed ties, likely leading to an
underestimate of their extent. Finally, we note that while we tried
to ensure an exhaustive and multi-layered search strategy, we are
unaware of any established method for identifying panel
publications that review or propose changes to disease definitions.
Notwithstanding these limitations, the study has strong clinical,
research, and policy relevance. Its novel focus on panels reviewing
and proposing changes to common disease definitions or
diagnostic criteria will help deepen understanding of the nature
of what’s been described as the ‘‘modern epidemic’’ of over-
diagnosis [2]. Moreover, the group of 16 publications includes
influential articles affecting the definition of 14 common condi-
tions and impacting directly on medical policy and practice
around the world.
The study findings are consistent with and help augment the
evidence-base about industry ties of influential medical profes-
sionals. The 2011 systematic review found 56%–87% of clinical
guideline writers had conflicts of interest [6], similar to our finding
of 75% across disease-defining panels. Kung and colleagues found
71% of guideline committee chairs had conflicts [9], again similar
to our findings. While these proportions may reflect the level of ties
among medical specialists more generally, they are in stark
contrast to IOM 2009 and 2011 reports calling for panels to
generally exclude people with conflicts of interest [5,8]. As
reported above, we found no change in the proportion of
members disclosing ties in the 2012 publications, after release of
both IOM reports.
At least two publications [20,21] made reference to members
believing industry ties did not influence their decision-making, and
we make no suggestion to the contrary. Indeed our data do not
support any inference industry ties are associated with widening
definitions or failure to rigorously assess potential harms of that
widening. With anemia in chronic kidney disease, a panel with a
high proportion of ties raised thresholds, effectively narrowing the
definition [33]. There will doubtless be other cases where diseases
have been widened by panels of medical specialists without
industry ties. Moreover, as Lurie and colleagues found in the
context of drug regulation, the financial conflicts of expert advisory
committees did not correlate significantly with their voting
outcomes [34]. Medicalization and over-diagnosis are driven by
many factors—technological, professional, commercial, legal, and
cultural [3].
While inferences of association or causation between industry
ties and expanding disease definitions cannot be drawn, our
findings can be considered in the context of broader evidence
about potentially distorting biases associated with widespread
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industry sponsorship and financial ties in medical research [35–
37], education [38], and practice [5], and in relation to ‘‘key
opinion leaders’’ who speak and consult for industry [39].
In 1999 Schwartz and Woloshin found changes to definitions of
high blood pressure, high cholesterol, diabetes, and overweight
would ‘‘dramatically inflate disease prevalence’’ and ‘‘ultimately
label 75% of the adult U.S. population as diseased’’ [40]. They
concluded the ‘‘extent to which new ‘patients’ would ultimately
benefit from early detection and treatment of these conditions is
unknown. Whether they would experience important physical or
psychological harm is an open question.’’ To what extent newly
created ‘‘patients’’ produced by widening disease definitions will
experience important harms remains a largely unanswered
question, over a decade later.
This study did not investigate the merits of the proposed
changes to the conditions identified. However, findings that
diagnostic thresholds are being lowered by panels dominated by
those with financial ties to multiple companies that may benefit
directly from those decisions raise questions about current
processes of disease definition. While it may be more difficult to
locate senior specialists without industry ties, two recent IOM
reports have encouraged such a change [5,8], and models already
exist for panels free of such conflicts, including the NIH consensus
development program [41].
Several unanswered questions arise from this study, which could
benefit from further investigation. Researchers might fruitfully
examine how definitions are changing over time, what dollar
amounts are being received from industry by panel members and
organisations that auspice them, and how panel proposals impact
on potential markets of sponsors. Most importantly enhanced
research and policy attention might be directed at designing new
processes for reviewing disease definitions, free of financial
conflicts of interest and informed by rigorous analysis of benefits
and harms.
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Editors’ Summary
Background. Health professionals generally base their
diagnosis of physical and mental disorders among their
patients on disease definitions and diagnostic thresholds
that are drawn up by expert panels and published as
statements or as part of clinical practice guidelines. These
disease definitions and diagnostic thresholds are reviewed
and updated in response to changes in disease detection
methods, treatments, medical knowledge, and, in the case of
mental illness, changes in cultural norms. Sometimes, the
review process widens disease definitions and lowers
diagnostic thresholds. Such changes can be beneficial. For
example, they might ensure that life-threatening conditions
are diagnosed early when they are still treatable. But the
widening of disease definitions can also lead to over-
diagnosis—the diagnosis of a condition in a healthy
individual that will never cause any symptoms and won’t
lead to an early death. Over-diagnosis can unnecessarily label
people as ill, harm healthy individuals by exposing them to
treatments they do not need, and waste resources that could
be used to treat or prevent ‘‘genuine’’ illness.
Why Was This Study Done? In recent years, evidence for
widespread financial and non-financial ties between phar-
maceutical companies and the health professionals involved
in writing clinical practice guidelines has increased, and
concern that these links may influence professional judg-
ments has grown. As a result, a 2011 report from the US
Institute of Medicine (IOM) recommended that, whenever
possible, guideline developers should not have conflicts of
interest, that a minority of the panel members involved in
guideline development should have conflicts of interest, and
that the chairs of these panels should be free of conflicts.
Much less is known, however, about the ties between
industry and the health professionals involved in reviewing
disease definitions and whether these ties might in some
way contribute to over-diagnosis. In this cross-sectional
study (an investigation that takes a snapshot of a situation at
a single time point), the researchers identify panels that have
recently made decisions about definitions or diagnostic
thresholds for conditions that are common in the US and
describe the industry ties among the panel members and the
changes in disease definitions proposed by the panels.
What Did the Researchers Do and Find? The researchers
identified 16 publications in which expert panels proposed
changes to the disease definitions and diagnostic criteria for
14 conditions that are common in the US such as
hypertension (high blood pressure) and Alzheimer disease.
The proposed changes widened the disease definition for
ten diseases, narrowed it for one disease, and had an unclear
impact for five diseases. Reasons included in the publications
for changing disease definitions included new evidence of
risk for people previously considered normal (pre-hyperten-
sion) and the emergence of new biomarkers, tests, or
treatments (Alzheimer disease). Only six of the panels
mentioned possible harms of the proposed changes and
none appeared to rigorously assess the downsides of
expanding definitions. Of the 15 panels involved in the
publications (one panel produced two publications), 12
included members who disclosed financial ties to multiple
companies. Notably, the commonest industrial ties among
these panels were to companies marketing drugs for the
disease being considered by that panel. On average, 75% of
panel members disclosed industry ties (range 0% to 100%) to
a median of seven companies each. Moreover, similar
proportions of panel members disclosed industry ties in
publications released before and after the 2011 IOM report.
What Do These Findings Mean? These findings show
that, for the conditions studied, most panels considering
disease definitions and diagnostic criteria proposed changes
that widened disease definitions and that financial ties with
pharmaceutical companies with direct interests in the
therapeutic area covered by the panel were common among
panel members. Because this study does not include a
comparison group, these findings do not establish a causal
link between industry ties and proposals to change disease
definitions. Moreover, because the study concentrates on a
subset of common diseases in the US setting, the general-
izability of these findings is limited. Despite these and other
study limitations, these findings provide new information
about the ties between industry and influential medical
professionals and raise questions about the current process-
es of disease definition. Future research, the researchers
suggest, should investigate how disease definitions change
over time, how much money panel members receive from
industry, and how panel proposals affect the potential
market of sponsors. Finally it should aim to design new
processes for reviewing disease definitions that are free from
potential conflicts of interest.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001500.
N A PLOS Medicine Research Article by Knu¨ppel et al.
assesses the representation of ethical issues in general
clinical practice guidelines on dementia care
N Wikipedia has a page on medical diagnosis (note:
Wikipedia is a free online encyclopedia that anyone can
edit; available in several languages)
N An article on over-diagnosis by two of the study authors is
available; an international conference on preventing over-
diagnosis will take place this September
N The 2011 US Institute of Medicine report ‘‘Clinical Practice
Guidelines We Can Trust’’ is available
N A PLOS Medicine Essay by Lisa Cosgrove and Sheldon
Krimsky discusses the financial ties with industry of panel
members involved in the preparation of the latest revision
of the American Psychiatric Association’s Diagnostic and
Statistical Manual of Mental Disorders (DSM), which
provides standard criteria for the classification of mental
disorders
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